Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease

NCT01522547 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia, Sickle Cell

Interventions

DRUG: pomalidomide

Sponsor

Celgene